Stoler MH, Wright TC Jr., Sharma A, et al. Am J Clin Pathol 2011;135:468–475OpenUrlAbstract/FREE Full Text

For some time the Hybrid Capture 2™ (HC2) Test (QIAGEN, Gaithersburg, MD, USA) was really the only commercially available test for high-risk human papillomavirus (HR-HPV) detection. However, as the application of HPV testing for cervical disease management became increasingly evidenced, this led to a rapid increase in other major commercial entities producing HPV tests for their diagnostic portfolios. The majority (like HC2) detect a pool of common high-risk types in aggregate; however, some, like the Cobas™ 4800 HPV Test (Roche Molecular Systems, Pleasanton, CA, USA), also offer limited genotyping. The ATHENA trial was designed to assess the clinical performance of …